The Potential Demand for and Strategic Use of an HIV-1 Vaccine in Southern India
Even a modestly effective HIV-1 vaccine would be highly useful in India and could avoid millions of deaths. How should such a vaccine be introduced? Based on evidence of adoption of other vaccines in India, current levels of spending on them and co...
| Main Authors: | , , |
|---|---|
| Language: | English en_US |
| Published: |
World Bank, Washington, DC
2014
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/2003/05/2378824/potential-demand-strategic-use-hiv-1-vaccine-southern-india http://hdl.handle.net/10986/18219 |
| Summary: | Even a modestly effective HIV-1 vaccine
would be highly useful in India and could avoid millions of
deaths. How should such a vaccine be introduced? Based on
evidence of adoption of other vaccines in India, current
levels of spending on them and coverage of prevention
programs targeting both high- and low-risk groups, Seshadri,
Subramaniyam, and Jha assess the potential demand for and
strategic use of an HIV-1 vaccine in the four southern
Indian states of Andhra Pradesh, Karnataka, Maharashtra, and
Tamil Nadu. The authors also discuss potential strategies
for delivery of the vaccine, prioritization for vaccination,
and the political economy of such a vaccine in India.
Assuming a vaccine cost of $10 a dose and including
estimated delivery costs, the total cost of vaccinating 21.6
million adolescents 11-14 years of age and 1 percent of
adults would be Rs. 12.25 billion (US$ 245 million). To
maintain the vaccination rate in the 11-14 year old cohort,
an additional 6.77 million in that age range would have to
be vaccinated each year, at a vaccine cost of Rs. 3.39
billion (US$ 67.5 million). An HIV-1 vaccine will greatly
reduce HIV/AIDS in India, but it will not be a panacea.
There will be a continued need for effective prevention
programs to guard against behavior reversals or an imperfect
vaccine. Key inputs for prevention, immunization, and
treatment programs such as identification of various groups
that could be immunized (vulnerable groups or general
populations), strengthened surveillance, capacity building,
operations research, and evaluation at local levels will
continue to require intensive support. |
|---|